Richard M. Stone
Distinguished in Hairy Cell Leukemia (HCL)

Dr. Richard M. Stone

Hematology Oncology | Hematology | Oncology
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Adult Leukemia Program
450 Brookline Avenue, 
Boston, MA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
41 Years of Experience
Distinguished in Hairy Cell Leukemia (HCL)
Brigham and Women’s Hospital
Dana-Farber Cancer Institute, Adult Leukemia Program
450 Brookline Avenue, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Richard Stone is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Stone has been practicing medicine for over 41 years and is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 505 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Hairy Cell Leukemia (HCL).

Graduate Institution
Harvard Medical School/ BWH, 1981
Residency
Brigham and Women's Hospital, 1984
Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in MA
Board Certifications
Hematology
Internal Medicine
Medical Oncology
Fellowships
Dana-Farber Cancer Institute, 1987
Hospital Affiliations
Brigham And Women's Hospital
Languages Spoken
English
Gender
Male
Awards
Boston Magazine Top Doctor
2022
Castle Connolly America's Top Doctors
2022

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Neighborhood
  • MANAGED MEDICAID PLAN
  • MEDICARE ASSISTANCE PROGRAM
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
NH Healthy Families
  • EPO
  • MANAGED MEDICAID PLAN
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

Dana-Farber Cancer Institute, Adult Leukemia Program
450 Brookline Avenue, Boston, MA 02115
Call: 617-632-2214

Additional Areas of Focus

Dr. Stone has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Acute Myeloid Leukemia (AML)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Phase Ib/II Investigator Initiated Study of the IDH1-Mutant Inhibitor Ivosidenib (AG120) With the BCL2 Inhibitor Venetoclax +/- Azacitidine in IDH1-Mutated Hematologic Malignancies
Enrollment Status: Recruiting
Publish Date: October 03, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, Ivosidenib, Venetoclax
Study Phase: Phase 1/Phase 2
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase 2 Study of Mitoxantrone, Etoposide, and Cytarabine (MEC) Plus Lenalidomide for the Treatment of Adult Patients With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Drug
Study Drugs: Etoposide, Cytarabine, Lenalidomide, Mitoxantrone
Study Phase: Phase 2
A Phase 1 Study of LY3214996, an ERK1/2 Inhibitor, in Patients With AML Who Are Not Candidates for Standard Therapy
A Phase 1 Study of LY3214996, an ERK1/2 Inhibitor, in Patients With AML Who Are Not Candidates for Standard Therapy
Enrollment Status: Completed
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: LY3214996
Study Phase: Phase 1
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase I/II Trial of the MUC1 Inhibitor, GO-203-2C in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drugs: GO-203-2C, Decitabine
Study Phase: Phase 1/Phase 2
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission
A Randomized Phase II Clinical Trial of Dendritic Cell/AML Fusion Cell Vaccine Versus Observation in Patients Who Achieve a Chemotherapy-induced Remission
Enrollment Status: Completed
Publish Date: September 27, 2024
Intervention Type: Other, Biological
Study Drug: Dendritic Cell Fusion Vaccine
Study Phase: Phase 2
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Enrollment Status: Terminated
Publish Date: June 02, 2022
Intervention Type: Procedure, Drug
Study Drug: Decitabine
Study Phase: Phase 2
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
View 6 Less Clinical Trials

505 Total Publications

Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid Leukemia.
Prognostic and Therapeutic Implications of BRAF Mutations in Acute Myeloid Leukemia.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
View All 505 Publications
Similar Doctors
Daniel J. Deangelo
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Daniel J. Deangelo
Hematology Oncology | Oncology | Hematology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Daniel J. Deangelo
Hematology Oncology | Oncology | Hematology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Daniel Deangelo is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Deangelo is rated as an Elite provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Systemic Mastocytosis, Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Deangelo is currently accepting new patients.

Distinguished in Hairy Cell Leukemia (HCL)
Dr. David C. Fisher
Hematology Oncology | Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. David C. Fisher
Hematology Oncology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
617-632-3000
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Fisher is a Hematologist Oncology specialist and an Oncologist in Boston, Massachusetts. Dr. Fisher is rated as an Elite provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Cutaneous T-Cell Lymphoma (CTCL), T-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy. Dr. Fisher is currently accepting new patients.

Eric S. Winer
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Eric S. Winer
Hematology Oncology | Hematology | Oncology
Distinguished in Hairy Cell Leukemia (HCL)
Dr. Eric S. Winer
Hematology Oncology | Hematology | Oncology

Dana-Farber Cancer Institute, Inc.

450 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients

Eric Winer is a Hematologist Oncology specialist and a Hematologist in Boston, Massachusetts. Dr. Winer is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelogenous Leukemia (CML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Winer is currently accepting new patients.

VIEW MORE HAIRY CELL LEUKEMIA (HCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Stone's expertise for a condition
ConditionClose
  • Elite
  • Acute Myeloid Leukemia (AML)
    Dr. Stone is
    Elite
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Acute Promyelocytic Leukemia
    Dr. Stone is
    Elite
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Leukemia
    Dr. Stone is
    Elite
    . Learn about Leukemia.
    See more Leukemia experts
  • Myelodysplastic Syndrome (MDS)
    Dr. Stone is
    Elite
    . Learn about Myelodysplastic Syndrome (MDS).
    See more Myelodysplastic Syndrome (MDS) experts
  • Distinguished
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Stone is
    Distinguished
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Stone is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Stone is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Childhood Acute Myeloid Leukemia
    Dr. Stone is
    Distinguished
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Chronic Myelogenous Leukemia (CML)
    Dr. Stone is
    Distinguished
    . Learn about Chronic Myelogenous Leukemia (CML).
    See more Chronic Myelogenous Leukemia (CML) experts
  • Chronic Myelomonocytic Leukemia (CMML)
    Dr. Stone is
    Distinguished
    . Learn about Chronic Myelomonocytic Leukemia (CMML).
    See more Chronic Myelomonocytic Leukemia (CMML) experts
View All 14 Distinguished Conditions
  • Advanced
  • Acute Eosinophilic Pneumonia
    Dr. Stone is
    Advanced
    . Learn about Acute Eosinophilic Pneumonia.
    See more Acute Eosinophilic Pneumonia experts
  • Agranulocytosis
    Dr. Stone is
    Advanced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anemia
    Dr. Stone is
    Advanced
    . Learn about Anemia.
    See more Anemia experts
  • Aplastic Anemia
    Dr. Stone is
    Advanced
    . Learn about Aplastic Anemia.
    See more Aplastic Anemia experts
  • Bone Marrow Aspiration
    Dr. Stone is
    Advanced
    . Learn about Bone Marrow Aspiration.
    See more Bone Marrow Aspiration experts
  • Castleman Disease
    Dr. Stone is
    Advanced
    . Learn about Castleman Disease.
    See more Castleman Disease experts
View All 16 Advanced Conditions
  • Experienced
  • Acute Monoblastic Leukemia (AmoL)
    Dr. Stone is
    Experienced
    . Learn about Acute Monoblastic Leukemia (AmoL).
    See more Acute Monoblastic Leukemia (AmoL) experts
  • Adult Immune Thrombocytopenia
    Dr. Stone is
    Experienced
    . Learn about Adult Immune Thrombocytopenia.
    See more Adult Immune Thrombocytopenia experts
  • Adult Soft Tissue Sarcoma
    Dr. Stone is
    Experienced
    . Learn about Adult Soft Tissue Sarcoma.
    See more Adult Soft Tissue Sarcoma experts
  • B-Cell Lymphoma
    Dr. Stone is
    Experienced
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
  • Blood Clots
    Dr. Stone is
    Experienced
    . Learn about Blood Clots.
    See more Blood Clots experts
  • Bone Marrow Transplant
    Dr. Stone is
    Experienced
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.